Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z.

J Neurosci. 2010 Feb 3;30(5):1788-97. doi: 10.1523/JNEUROSCI.5604-09.2010.

2.

Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H.

Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. Epub 2015 Jun 29.

3.

(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.

Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL.

Neurobiol Dis. 2014 Aug;68:190-9. doi: 10.1016/j.nbd.2014.04.021. Epub 2014 May 14.

PMID:
24830390
4.

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R.

Hum Mol Genet. 2016 Mar 1;25(5):951-63. doi: 10.1093/hmg/ddv628. Epub 2016 Jan 6.

5.

Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.

Walker MD, Volta M, Cataldi S, Dinelle K, Beccano-Kelly D, Munsie L, Kornelsen R, Mah C, Chou P, Co K, Khinda J, Mroczek M, Bergeron S, Yu K, Cao LP, Funk N, Ott T, Galter D, Riess O, Biskup S, Milnerwood AJ, Stoessl AJ, Farrer MJ, Sossi V.

J Parkinsons Dis. 2014;4(3):483-98. doi: 10.3233/JPD-140344.

PMID:
25000966
6.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019. Epub 2015 Feb 28.

PMID:
25731749
7.

Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.

Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, Milnerwood AJ.

Parkinsonism Relat Disord. 2015 Oct;21(10):1156-63. doi: 10.1016/j.parkreldis.2015.07.025. Epub 2015 Aug 1.

PMID:
26282470
8.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

9.

Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.

Matikainen-Ankney BA, Kezunovic N, Mesias RE, Tian Y, Williams FM, Huntley GW, Benson DL.

J Neurosci. 2016 Jul 6;36(27):7128-41. doi: 10.1523/JNEUROSCI.3314-15.2016.

10.

The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.

Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD.

J Neurosci. 2015 Aug 12;35(32):11190-5. doi: 10.1523/JNEUROSCI.0040-15.2015.

11.

G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.

Xiao Q, Yang S, Le W.

J Neural Transm (Vienna). 2015 Dec;122(12):1645-57. doi: 10.1007/s00702-015-1438-9. Epub 2015 Aug 8.

PMID:
26253900
12.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61. Epub 2011 Jun 9.

13.

Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.

Pan PY, Li X, Wang J, Powell J, Wang Q, Zhang Y, Chen Z, Wicinski B, Hof P, Ryan TA, Yue Z.

J Neurosci. 2017 Nov 22;37(47):11366-11376. doi: 10.1523/JNEUROSCI.0964-17.2017. Epub 2017 Oct 20.

PMID:
29054882
14.

Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

Lee JW, Tapias V, Di Maio R, Greenamyre JT, Cannon JR.

Neurobiol Aging. 2015 Jan;36(1):505-18. doi: 10.1016/j.neurobiolaging.2014.07.011. Epub 2014 Jul 15.

15.

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.

Longo F, Russo I, Shimshek DR, Greggio E, Morari M.

Neurobiol Dis. 2014 Nov;71:62-73. doi: 10.1016/j.nbd.2014.07.013. Epub 2014 Aug 6.

16.

Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.

Nikonova EV, Xiong Y, Tanis KQ, Dawson VL, Vogel RL, Finney EM, Stone DJ, Reynolds IJ, Kern JT, Dawson TM.

Hum Mol Genet. 2012 Jan 1;21(1):163-74. doi: 10.1093/hmg/ddr451. Epub 2011 Oct 4.

17.

No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.

Garcia-Miralles M, Coomaraswamy J, Häbig K, Herzig MC, Funk N, Gillardon F, Maisel M, Jucker M, Gasser T, Galter D, Biskup S.

PLoS One. 2015 Apr 1;10(4):e0118947. doi: 10.1371/journal.pone.0118947. eCollection 2015.

18.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

19.

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.

Qin Q, Zhi LT, Li XT, Yue ZY, Li GZ, Zhang H.

CNS Neurosci Ther. 2017 Feb;23(2):162-173. doi: 10.1111/cns.12660. Epub 2016 Dec 9.

20.

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG.

Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9.

Supplemental Content

Support Center